Allogeneic Mesenchymal Stem Cells: Agents of Immune Modulation

被引:105
作者
English, Karen [2 ]
Mahon, Bernard P. [1 ]
机构
[1] Natl Univ Ireland Maynooth, Cellular Immunol Lab, Inst Immunol, Maynooth, Kildare, Ireland
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg Sci, Transplantat Res Immunol Grp, Oxford OX3 9DU, England
基金
爱尔兰科学基金会;
关键词
MESENCHYMAL STEM CELLS; IMMUNOLOGY; CELL THERAPY; REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; VERSUS-HOST-DISEASE; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; IN-VIVO; INTERFERON-GAMMA; IFN-GAMMA; B-CELLS; INHIBIT;
D O I
10.1002/jcb.23119
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adult mesenchymal stem cells possess a remarkably diverse array of immunosuppressive characteristics. The capacity to suppress the regular processes of allogeneic rejection, have allowed the use of tissue mismatched cells as therapeutic approaches in regenerative medicine and as agents of immune deviation. This review describes recent advances in understanding the mechanistic basis of mesenchymal stromal or stem cells (MSC) interaction with innate immunity. Particular emphasis is placed on the effect of Toll-like receptor signalling on MSC and a hypothesis that innate immune signals induce a 'licensing switch' in MSC is put forward. The mechanisms underlying MSC suppression of T cell responses and induction of regulatory populations are surveyed. Conflicting data regarding the influence of MSC on B cell function are outlined and discussed. Finally the limits to MSC mediated immune modulation are discussed with reference to the future clinical application of novel cell therapies. J. Cell. Biochem. 112: 1963-1968, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:1963 / 1968
页数:6
相关论文
共 51 条
[1]   Mesenchymal stem cells suppress B-cell terminal differentiation [J].
Asari, Sadaki ;
Itakura, Shin ;
Ferreri, Kevin ;
Liu, Chih-Pin ;
Kuroda, Yoshikazu ;
Kandeel, Fouad ;
Mullen, Yoko .
EXPERIMENTAL HEMATOLOGY, 2009, 37 (05) :604-615
[2]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[3]  
Bianco P, 2010, HUM GENE THER, V21, P1057, DOI 10.1089/hum.2010.136
[4]   MESENCHYMAL STEM-CELLS [J].
CAPLAN, AI .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650
[5]   Why are MSCs therapeutic? New data: new insight [J].
Caplan, Al .
JOURNAL OF PATHOLOGY, 2009, 217 (02) :318-324
[6]   Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells [J].
Casiraghi, Federica ;
Azzollini, Nadia ;
Cassis, Paola ;
Imberti, Barbara ;
Morigi, Marina ;
Cugini, Daniela ;
Cavinato, Regiane Aparecida ;
Todeschini, Marta ;
Solini, Samantha ;
Sonzogni, Aurelio ;
Perico, Norberto ;
Remuzzi, Giuseppe ;
Noris, Marina .
JOURNAL OF IMMUNOLOGY, 2008, 181 (06) :3933-3946
[7]   Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells [J].
Chen, Lei ;
Zhang, Wei ;
Yue, Han ;
Han, Qin ;
Chen, Bin ;
Shi, Mingxia ;
Li, Jing ;
Li, Binzong ;
You, Shengguo ;
Shi, Yufang ;
Zhao, Robert Chunhua .
STEM CELLS AND DEVELOPMENT, 2007, 16 (05) :719-731
[8]   Human mesenchymal stem cells modulate B-cell functions [J].
Corcione, A ;
Benvenuto, F ;
Ferretti, E ;
Giunti, D ;
Cappiello, V ;
Cazzanti, F ;
Risso, M ;
Gualandi, F ;
Mancardi, GL ;
Pistoia, V ;
Uccelli, A .
BLOOD, 2006, 107 (01) :367-372
[9]   Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism [J].
Djouad, Farida ;
Charbonnier, Louis-Marie ;
Bouffi, Carine ;
Louis-Plence, Pascale ;
Bony, Claire ;
Apparailly, Florence ;
Cantos, Celine ;
Jorgensen, Christian ;
Noel, Daniele .
STEM CELLS, 2007, 25 (08) :2025-2032
[10]   Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells [J].
English, K. ;
Ryan, J. M. ;
Tobin, L. ;
Murphy, M. J. ;
Barry, F. P. ;
Mahon, B. P. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 156 (01) :149-160